SCHEMBL1338440

SCHEMBL1338440

Cn1c(=O)c(-c2ccc(Cl)cc2Cl)cc2c3cc(-c4ccn[nH]4)ccc3[nH]c21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP2 P11137 1/20 0.45
▸ NOTUM Q6P988 4/20 0.39
▸ POLB P06746 1/20 0.39
▸ PTPN11 Q06124 1/20 0.39
▸ JAK2 O60674 1/20 0.38
▸ IDH1 O75874 1/20 0.38
▸ PIM1 P11309 1/20 0.38
▸ BRD4 O60885 2/20 0.36
▸ BRD2 P25440 1/20 0.36
▸ BRD3 Q15059 1/20 0.36
▸ CNR1 P21554 5/20 0.36
▸ CNR2 P34972 5/20 0.36
▸ HSD11B1 P28845 1/20 0.36
▸ F2RL3 Q96RI0 1/20 0.35
▸ TNKS O95271 1/20 0.34
▸ EGFR P00533 1/20 0.34
▸ ALOX5 P09917 1/20 0.34
▸ ADORA3 P0DMS8 1/20 0.34
▸ GABRA1 P14867 1/20 0.34
▸ ADRA2C P18825 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1338048 0.83 NOTUM (0.38) NOTUMCNR1CNR2HSD11B1F2RL3
SCHEMBL1338675 0.83 CNR1 (0.37) CNR1CNR2HSD11B1F2RL3EGFR
SCHEMBL1338074 0.82 L3MBTL1 (0.40) MAP2NOTUMPOLBPTPN11PIM1
SCHEMBL3139766 0.81 MAP2 (0.45) MAP2NOTUMPOLBPTPN11JAK2
SCHEMBL1339352 0.80 TLR8 (0.39) CNR1CNR2HSD11B1F2RL3TNKS
SCHEMBL1338963 0.80 ABL1 (0.38) IDH1CNR1CNR2HSD11B1F2RL3
SCHEMBL958804 0.80 F2RL3 (0.46) CNR1CNR2HSD11B1F2RL3TNKS
SCHEMBL1339374 0.78 CNR1 (0.38) POLBCNR1CNR2HSD11B1F2RL3
SCHEMBL1338065 0.78 PARP1 (0.41) POLBPIM1CNR1CNR2HSD11B1
SCHEMBL1336854 0.78 PARP1 (0.42) POLBPIM1BRD4CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 MAP2 2088/4885NOTUM 3400/4885POLB 1970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback